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Peripheral Arterial Disease and Ankle-Brachial Pressure Index as Predictors 
of Mortality in Residents of Metlika County, Slovenia
Aim To test how the presence of peripheral arterial disease predicted mortality of 
middle-aged and elderly residents of Metlika county, a rural area in southeastern 
Slovenia.
Methods In 1987, we interviewed and examined a representative cohort of 646 
subjects aged 45-80 years at inclusion without overt coronary or cerebrovascular 
disease, for cardiovascular risk factors and measured the ankle-brachial pressure 
index (ABPI). Peripheral arterial disease was defined as ABPI<0.90. The subjects 
were followed up 15 years or until death. All-cause mortality and cardiovascular 
mortality were assessed and compared between subjects with and without periph-
eral arterial disease in a multivariate model.
Results There were 580 subjects with normal ABPI and 66 subjects with periph-
eral arterial disease, among which 49 were asymptomatic and 17 had intermittent 
claudication. Because subjects with peripheral arterial disease were on average 10 
years older than those without peripheral arterial disease, the mere presence of 
peripheral arterial disease was not an independent predictor of mortality. How-
ever, there was a significant interaction of peripheral arterial disease with age, 
with a more pronounced adverse prognostic effect of peripheral arterial disease in 
younger than in older age groups. For a 55-year-old subject with peripheral arte-
rial disease, the hazard ratio of dying from any cause in the follow-up period was 
2.44 (95% confidence interval [CI], 1.15-4.96) in comparison to an age-matched 
subject without peripheral arterial disease, but at 75 years of age, the hazard ra-
tio decreased to only 0.71 (95% CI, 0.46-1.09). For cardiovascular mortality, the 
hazard ratio in the presence of peripheral arterial disease was 6.05 (95% CI, 1.87-
16.27) at 55 years and 0.92 (95% CI, 0.54-1.52) at 75 years. Among patients with 
peripheral arterial disease, each decrement of ABPI at inclusion by 0.10 signifi-
cantly increased the cardiovascular mortality after 15 years by 30% (P = 0.038).
Conclusion Peripheral arterial disease, even asymptomatic, is an important pre-
dictor of adverse cardiovascular prognosis in relatively young patients. Reduced 
ABPI is a strong, independent predictor of cardiovascular mortality in all patients 
with peripheral arterial disease.
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Clinical manifestation of peripheral arterial dis-
ease confirmed by reduced ankle-brachial pres-
sure index (ABPI) ranges from the common 
asymptomatic disease, to the less prevalent inter-
mittent claudication, to the relatively rare critical 
limb ischemia with rest pain, ulceration or gan-
grene (1). Even if peripheral arterial disease does 
not cause typical claudication, it reduces walking 
speed and walking endurance (2). Regardless of 
the clinical symptoms, reduced ABPI is a sign of 
hemodynamic disturbance in the arterial supply of 
the lower limbs, which is strongly associated with 
atherosclerosis in the coronary and carotid terri-
tories (3). Thus, peripheral arterial disease is asso-
ciated with increased mortality due to myocardial 
infarction and ischemic stroke. Several studies de-
scribed 2-3-fold greater mortality in patients with 
peripheral arterial disease in comparison with age-
matched controls with normal ABPI; patients 
with peripheral arterial disease had a 5-year mor-
tality of about 30% (4-9). Increasing severity of pe-
ripheral arterial disease, expressed as diminishing 
ABPI, progressively reduces survival (6-9).
Most previously studied cohorts were either 
patients referred for non-invasive vascular test-
ing (6) or patients with known risk factors such 
as hypertension (8) or hyperlipidemia (4). There 
is still little data on the prognostic value of large-
ly asymptomatic early-stage peripheral arterial dis-
ease in patients free of overt coronary or cerebro-
vascular disease in a community setting. We have 
focused on a representative sample of residents of 
Metlika county, a rural area in southeastern Slove-
nia to test how the presence of peripheral arterial 
disease, defined as ABPI<0.90, and the severity of 
peripheral arterial disease at inclusion, expressed as 
diminishing ABPI, affected all-cause mortality and 
cardiovascular mortality in a community setting.
Subjects and methods
Subjects
The study was carried out in Metlika county, a 
predominantly rural area in southeastern Slove-
nia. In 1987, the county had 8322 residents, of 
whom 3216 were aged between 45 and 80 years 
at the time of recruitment (10). From this age 
group, 708 were randomly selected from the list 
of appropriately aged residents by use of tables of 
random numbers.
Interviews and physical examinations were 
performed from January to March 1987. All sub-
jects continued using the usual medical care pro-
vided by their general physicians. Survival of our 
subjects was followed up for 15 years until study 
completion in 2002.
Systolic blood pressure in the ankles and 
arms of supine subjects was measured at baseline 
by sphygmomanometer cuffs and Doppler flow 
detector (11,12). ABPI was calculated by divid-
ing the average ankle arterial pressure (mean of 
posterior and anterior tibial artery) with the 
arm pressure. Values of ABPI of 0.91-1.50 were 
considered normal, whereas ABPI>1.50 indica-
tied rigid arterial walls and those subjects were 
excluded from further analysis. Subjects with 
ABPI<0.90 were considered to have peripheral 
arterial disease. Clinical symptoms of peripheral 
arterial disease were evaluated by the Rose ques-
tionnaire (13).
Clinically overt coronary or cerebrovascu-
lar disease was an exclusion criterion at baseline. 
Coronary heart disease was defined by a history 
of a myocardial infarction or angina pectoris ac-
cording to the Rose questionaire (13), by evi-
dence of an old myocardial infarction on the 
electrocardiogram on the basis of Minnesota 
codes (14), or by a history of coronary surgery 
or coronary angioplasty. Overt cerebrovascular 
disease, ie, stroke or transitory ischemic attack 
(TIA) was defined by an interviewer-adminis-
tered questionnaire, or as a report of stroke or 
TIA by a physician.
Major cardiovascular risk factors were evalu-
ated in the subjects. Hypertension was defined as 
a positive history of antihypertensive medication 
or 3 casual blood pressure measurements exceed-
ing 140 mm Hg of systolic pressure or 90 mm 
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Hg of diastolic pressure. Serum cholesterol was 
determined by the standard cholesterol oxidase-
peroxidase aminophenazone phenol (CHOD-
PAP) enzymatic method (15). Hypercholester-
olemia was defined as serum cholesterol >5.2 
mmol/L. Smokers were defined as those current-
ly smoking one or more cigarettes per day. Dia-
betes mellitus was defined as fasting hypergly-
cemia >8 mmol/L or by being included in the 
registry of patients with diabetes mellitus in the 
area. Weight and height were measured indors, 
in clothing without shoes, and the body mass in-
dex (BMI) was calculated as the weight (kg) di-
vided by the squared height (m). Overweight was 
defined as BMI>25.
Ascertainment of deaths
All deaths were ascertained through the Regis-
try of the Republic of Slovenia, issued by the In-
stitute of Health Protection of the Republic of 
Slovenia. A printed copy of this index, sorted by 
year of death, county of residence and name, was 
checked against the list of included patients with-
out knowledge of their peripheral arterial disease 
status. The death certificate for each match of 
names was than reviewed to assure the accuracy 
of identification. Analysis of the causes of death 
included data from hospital autopsies when 
available. The underlying cause of death was cod-
ed according to the International Classification 
of Diseases, version 10 (ICD-10) (16), for each 
deceased subject. Cardiac causes of death were 
defined as diagnoses with ICD-10 codes I11-I25 
(hypertensive and ishemic heart disease) and I44-
I50 (cardiac conduction disturbances, arrhyt-
mias, cardiac arrest, and heart failure). Cerebro-
vascular causes of death were defined as diagnoses 
with ICD codes I61-I64 (intracerebral bleeding 
and ischemic stroke). Cardiac and cerebrovascu-
lar diagnoses together comprised cardiovascular 
causes of death. Data analysis was completed in 
2003.
Statistical analysis
Differences in the baseline characteristics of sub-
jects with and those without peripheral arterial 
disease were evaluated by χ2 test for nominal vari-
ables and by two-tailed t-test for continuous vari-
ables. Overall survival of the the two groups was 
shown by Kaplan-Meier curves. Survival curves 
of the two groups (with and without peripheral 
arterial disease) were compared with the log-rank 
test, but since the two groups differed significant-
ly in many variables affecting survival, these con-
founding variables were taken into account by 
using the Cox proportional hazards regression 
model (17). With the regression model, the ef-
fect of the presence of peripheral arterial disease 
and the effect of ABPI on all-cause mortality and 
cardiovascular mortality was determined, where-
as all other variables were considered constant. 
In other words, the Cox model estimated the ra-
tio of hazards for two hypothetical individuals 
with equal values of all confounding variables, 
one with and the other without peripheral arte-
rial disease, and tested for the trend of linear low-
ering of ABPI in comparison with normal ABPI. 
In comparing the survival of our cohort with 
the general population of Slovenia, we used the 
transformation approach (18) based on the Slo-
vene mortality tables (10). Statistical analysis was 
performed with R 2.1.0 statistical software, a lan-
guage and environment for statistical computing 
(R Foundation for Statistical Computing, Vien-
na, Austria). P<0.05 was considered statistically 
significant.
Results
Of 708 randomly selected subjects, 685 (96.7%) 
participated in the study. Of those, 39 were ex-
cluded for mediocalcinosis and ABPI>1.50 
(n = 14), clinically overt coronary disease 
(n = 17), and overt cerebrovascular disease 
(n = 8). The remaining 646 participants still rep-
resented 20% of the population aged 45-80 years 
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in Metlika county. In the studied cohort, there 
were 66 patients with peripheral arterial disease, 
among which 49 were asymptomatic and 17 had 
claudication. The prevalence of peripheral arteri-
al disease increased with age from <5% in 55-59-
year age group to about 20% in 70–74-year age 
group and almost 35% in 75-80-year age group 
(Figure 1).
There was a predominance of women in our 
cohort, which was in accordance with the sex dis-
tribution in the population aged 45-80 years in 
Metlika county (Table 1). The subjects with pe-
ripheral arterial disease were on average 10 years 
older than their counterparts with normal ABPI, 
and had a significantly higher prevalence of 
smoking, arterial hypertension, hypercholesterol-
emia and diabetes (Table 2). About three-quar-
ters of subjects in both groups were overweight, 
with a BMI>25 kg/m2. The mean (±standard 
deviation) body mass index was 28.1 ± 4.4 in 
subjects without peripheral arterial disease and 
28.0 ± 5.3 in subjects with peripheral arterial dis-
ease (P = 0.92).
Mortality was much higher in subjects with 
peripheral arterial disease than in those without 
peripheral arterial disease (Figure 2). The dif-
ference by direct comparison would have been 
highly significant (P<0.001), but such a com-
parison was not justified because the subjects 
with peripheral arterial disease were on average 
10 years older at inclusion and also differed from 
the control group in all other risk factors except 
BMI (Table 2). Overall, the survival of our co-
hort, ie, subjects with and without peripheral ar-
terial disease, did not differ from survival of the 
whole Slovene population in the same calendar 
period (Figure 3).
Figure 1. Prevalence and symptoms of peripheral arterial disease 
(PAD) in the cohort stratified by age. Open bar – asymptomatic PAD, 
closed bar – claudication.
Figure 2. Kaplan-Meier estimates of the survival of the participants 
with (lower line) and those without peripheral arterial disease (upper 
line). The participants with peripheral arterial disease were on avera-
ge 10 years older at inclusion than subjects with normal ankle-brachial 
pressure index (ABPI).
Table 1. Baseline characteristics of participants with and without 
peripheral arterial disease (PAD)
 No. (%) of participants










Age at inclusion (y)* 58.0 ± 8.8 59.2 ± 9.2 66.4 ± 10.2 72.1 ± 5.2
Overweight 159 (75.4) 276 (74.8) 26 (66.7) 22 (81.5)
Hypercholesterolemia  36 (17.1)  47 (12.7) 16 (41.0) 12 (44.4)
Hypertension  83 (39.9) 169 (45.8) 18 (46.2) 22 (81.5)
Diabetes mellitus  24 (11.4)  69 (18.7) 10 (25.6)  9 (33.3)
Smoking 100 (47.4)  14 (3.8) 34 (87.2)  2 (7.4)
*Mean±standard deviation.
Table 2. Comparison of risk factors in participants with normal 
ankle-brachial pressure index and without peripheral arterial 
disease (PAD)
No. (%) of participants
Risk factor without PAD with PAD P
Overweight 435 (75.0) 48 (72.7)  0.687*
Hypercholesterolemia  83 (14.3) 28 (42.4) <0.001*
Hypertension 252 (43.4) 40 (60.6)  0.008*
Diabetes  93 (16.0) 19 (28.8)  0.010*
Smoking 114 (19.7) 36 (54.5) <0.001*
Age at inclusion (y) 58.8 ± 9.0 68.7 ± 8.0 <0.001†
*χ2 test.
†t test, mean±standard deviation.
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The causes of death in patients with periph-
eral arterial disease were predominantly cardio-
vascular with cardiac causes and cerebrovascular 
causes together accounting for 67% of deaths, as 
opposed to 45% of cardiovascular deaths among 
subjects without peripheral arterial disease 
(P = 0.007). Cardiac causes, mainly myocardial 
infarction and heart failure, accounted for 43% 
or deaths among patients with peripheral arte-
rial disease and 31% in patients without periph-
eral arterial disease (P = 0.130). Cerebrovascular 
causes, mainly cerebrovascular stroke, account-
ed for 24% of deaths in patients with peripheral 
arterial disease and 14% in patients without pe-
ripheral arterial disease (P = 0.090). The causes 
of death among patients with peripheral arterial 
disease were stratified according to age at inclu-
sion (Figure 4).
Since the subjects with peripheral arterial dis-
ease were significantly older than the subjects 
without peripheral arterial disease, we expect-
ed that a large proportion of the mortality dif-
ference (Figure 2) was due to age. Indeed, in the 
multivariate model that included age in years 
over 45 and the presence of peripheral arteri-
al disease, the effect of peripheral arterial disease 
was no longer significant, with a regression co-
efficient of 0.235 ± 0.17 (P = 0.177). There was 
Figure 3. Comparison by the transformation approach (16) of the 
observed survival in the Metlika cohort (subjects with and without 
peripheral arterial disease taken together). Grey line – survival of the 
Slovene population in the same calendar period; full line – the cohort; 
dashed line – 95% confidence intervals for the observed survival in 
the cohort.
Figure 4. Causes of death in patients with peripheral arterial disease 
over 15 years of follow up. None of the subjects in the 45-50-year 
age group at inclusion died, but a large proportion of the older parti-
cipants died. Cardiac and cerebrovascular causes, together denoted 
as cardiovascular deaths, accounted for two-thirds of mortality among 
patients with peripheral arterial disease. Malignancies were the most 
common cause of non-cardiovascular death. Open bar – other; gray 
bar – cerebrovascular causes; closed bar – cardiac causes.
Figure 5. The risk of dying in the next 15 years in the presence of peripheral arterial disease (PAD) in comparison with risk of an age-matched and 
other risk factor-matched person with normal ankle-brachial pressure index, as a function of age at inclusion. The hazard ratios (full line) for all-cause 
mortality (A) and cardiovascular mortality (B) are shown with 95% confidence intervals (dashed lines).
Croat Med J 2006;47:327-334
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also no significant interaction of peripheral arte-
rial disease and male sex, indicating that periph-
eral arterial disease affected both sexes equally in 
terms of cardiovascular prognosis.On the other 
hand, the prognostic effect of peripheral arterial 
disease changed with age, being more much im-
portant for survival of younger subjects. When 
the interaction of age and peripheral arterial dis-
ease was included in the model, the effect of pe-
ripheral arterial disease was significant even after 
including all other covariates in the model. From 
the interaction of age and peripheral arterial dis-
ease (Table 3), we calculated that the hazard ra-
tio of dying in the next 15 years was 2.44 (95% 
confidence interval [CI], 1.15–4.96) for a 55-
year-old subject with peripheral arterial disease 
in comparison with a subject without peripher-
al arterial disease; for a subject aged 75 years, the 
hazard ratio was reduced to 0.71 (95% CI, 0.46–
1.09) (Figure 5A).
Similarly, in analyzing cardiovascular mortal-
ity by the Cox proportional hazards model, the 
same variables had a significant adverse effect on 
survival (Table 4). Again, the negative prognos-
tic effect of peripheral arterial disease diminished 
with advancing age. The hazard ratio for dying of 
cardiovascular causes in the observed period was 
6.05 (95% CI, 1.87–16.27) for a 55-year-old sub-
ject with peripheral arterial disease in comparison 
with a subject without peripheral arterial disease, 
but the hazard ratio decreased to only 0.92 (95% 
CI, 0.54–1.52) at age of 75 years (Figure 5B).
When actual values of ABPI were analyzed, 
we found a significant association between the 
value of ABPI at inclusion and subsequent car-
diovascular mortality among the peripheral arte-
rial disease patients with a regression coefficient 
of -2.44 ± 1.18 (P = 0.038). In a multivariate 
model, even age was no longer a significant in-
dependent predictor of cardiovascular mortali-
ty when ABPI was taken into account, but each 
decrement of ABPI by 0.1 increased the hazard 
of dying from cardiovascular causes in the next 
15 years by a factor of 1.3.
Discussion
We found that the incidence of peripheral arte-
rial disease notably increased after the age of 55-
60 years in a representative sample of residents of 
Metlika county. This finding was in accordance 
with the published epidemiological data for in-
termittent claudication (19). In all age groups, 
asymptomatic peripheral arterial disease was 
more prevalent than intermitent claudication, 
as reported previously in the PARTNERS study 
(1). In our cohort, there were no cases of critical 
limb ischemia at inclusion or as a cause of death, 
emphasizing that patients with peripheral arteri-
al disease predominantly die from associated cor-
onary and cerebrovascular atherothrombosis and 
not from limb gangrene (3).
The novel finding of our study was that the 
adverse prognostic effect of peripheral arterial 
disease strongly depended on subjects’ age at in-
clusion in the study. For a person found to have 
peripheral arterial disease at 55 years of age, even 
though peripheral arterial disease was largely still 
asymptomatic, the hazard of dying from any 
cause in the next 15 years was more than double 
Table 3. All-cause mortality analyzed by the Cox proportional 
hazards model that included the interaction of peripheral arterial 
disease (PAD) and age*
Factor β HR SE(β) Z P
PAD   1.51 4.51 0.51     2.96  0.003
Age   0.12 1.12 0.01 13.19 <0.001
Hypertension   0.34 1.40 0.13     2.51  0.012
Smoking   0.85 2.33 0.15     5.73 <0.001
Age and PAD interaction -0.06 0.94 0.02   -3.16  0.002
*Age was measured in number of years over 45. Abbreviations: HR – hazard ratio, SE 
– standard error, Z – normal deviate equal to β/SE(β).
Table 4. Cardiovascular mortality analyzed by the Cox propor-
tional hazards model that included the interaction of peripheral 
arterial disease (PAD) and age*
Factor β HR SE(β) Z P
PAD   2.74 15.53 0.72     3.82 <0.001
Age   0.15   1.16 0.01 10.83 <0.001
Hypertension   0.42   1.53 0.19     2.18  0.029
Smoking   0.46   1.58 0.22     2.05  0.040
Age and PAD interaction -0.09   0.91 0.03   -3.54  0.004
*Age was measured in number of years over 45. Abbreviations: HR – hazard ratio, SE 
– standard error, Z – normal deviate equal to β/SE(β).
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that of a risk factor-matched person without pe-
ripheral arterial disease, and the hazard ratio for 
cardiovascular mortality was more than 6-times 
greater. With advancing age, the hazard ratios 
of peripheral arterial disease for all cause mortal-
ity and cardiovascular mortality diminished, and 
the risk of dying in the next 15 years was approx-
imately equal – within 95% confidence intervals 
– among 75-year-old subjects with or without 
peripheral arterial disease. The most obvious rea-
son for the diminishing adverse prognostic effect 
of peripheral arterial disease with advancing age is 
that the closer people get to the end of their pre-
dicted life span, the less any adverse prognostic 
sign matters. However, there may be additional 
reasons for the greater adverse prognostic effect 
of peripheral arterial disease at a younger age. The 
first possibility is that premature coronary and 
carotid atherosclerosis in conjunction with pe-
ripheral arterial disease carries a worse progno-
sis than coronary and carotid atherosclerosis that 
develops in older individuals irrespective of pe-
ripheral arterial disease. The second possibility is 
that younger people with peripheral arterial dis-
ease were less aggressively treated against athero-
thrombotic events than older ones. It is notewor-
thy that we found no differences between men 
and women regarding the prognostic impact of 
peripheral arterial disease.
The severity of peripheral arterial disease, 
measured as diminishing ABPI, was a strong, in-
dependent predictor of cardiovascular death in 
our study, which is in accordance with findings 
published previously (6-9,20,21). Each decre-
ment of ABPI by 0.1 at inclusion increased the 
risk of subsequent cardiovascular death by 30%. 
It is well known that with increasing severity of 
peripheral arterial disease, the atherosclerotic 
burden is increased also in the coronary and in 
the carotid vascular bed (3,22,23).
To prevent premature disability and mor-
tality from cardiovascular diseases, early screen-
ing is recommended together with assessment of 
total cardiovascular risk (24). Measurement of 
ABPI should become a component of cardiovas-
cular risk assessment, especially as we now have 
effective pharmacological treatment for cardio-
vascular risk reduction in patients with periph-
eral arterial disease. Antiplatelet treatment (25), 
lipid-lowering statins (26), and antihyperten-
sive therapy, especially ramipril (27), have been 
shown to reduce cardiovascular mortality by at 
least 20% each, so the combined pharmacologi-
cal approach should reduce the risk of premature 
death by about 50%. Since its is no longer ethical 
to perform a placebo-controlled trial of the rec-
ommended pharmacological prevention of ath-
erothrombosis in patents with peripheral arteri-
al disease, a prospective follow-up of adequately 
treated patients with peripheral arterial disease in 
comparison to apparently healthy controls will 
be welcome.
In conclusion, the presence of peripheral ar-
terial disease, even asymptomatic, is an impor-
tant predictor of adverse cardiovascular progno-
sis in relatively young patients, and our study has 
confirmed that diminishing values of ABPI are 
strong independent predictors of cardiovascular 
mortality. Since the overall mortality of our co-
hort did not differ from mortality of the whole 
Slovenia in the corresponding calendar years 
(10), our results might be relevant for the whole 
country and possibly at the international level, 
because cardiovascular morbidity and mortality 
of Slovenia corresponds to that in Central Eu-
rope (10).
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